Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$397.48 USD

397.48
682,467

-0.22 (-0.06%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $397.50 +0.02 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VRTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Vertex Pharmaceuticals Incorporated [VRTX]

Reports for Purchase

Showing records 281 - 300 ( 323 total )

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 281

08/03/2011

Company Report

Pages: 8

2Q11 Results Mark Robust Incivek Launch

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 282

02/25/2011

Company Report

Pages: 6

Better than Expected Results with VX-770

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 283

02/24/2011

Company Report

Pages: 7

Upgrading to Relative OUTPERFORM and Raising PT to $51

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 284

02/14/2011

Industry Report

Pages: 5

Biotechnology / Biopharmaceuticals - Potential Q1:11 Movers

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 285

02/14/2011

Daily Note

Pages: 5

Potential Q1:11 Movers

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 286

02/06/2011

Company Report

Pages: 7

Anticipating Telaprevir Launch in May - Raising Target Price from $45 to $48

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 287

02/03/2011

Company Report

Pages: 7

Raising PT to $42 on Increasing Pricing of CF Franchise; Q4:10 Earnings Uneventful; Multiple Milestones in H1:11

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 288

01/21/2011

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of January 23

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 289

01/09/2011

Industry Report

Pages: 5

2011 - Competition and Complexity Intensify for HCV

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 10.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 290

11/18/2010

Company Report

Pages: 7

Interim ASPIRE Data of TMC435 Encouraging

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 291

11/11/2010

Company Report

Pages: 4

Plans to Evaluate Three-Drug All-Oral Regimen

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 292

11/08/2010

Industry Report

Pages: 19

Wrapping Up AASLD 2010 with Dr. Zeuzem

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 50.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 293

11/04/2010

Company Report

Pages: 9

Telaprevir Beats Boceprevir Across the Board at AASLD

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 294

11/02/2010

Company Report

Pages: 6

Planned NDA Submission 4Q10 on Track

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 295

10/26/2010

Company Report

Pages: 6

3Q10 Results Point to Prelaunch Buildup

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 296

10/26/2010

Company Report

Pages: 7

Q3 Earnings; Corporate Updates; Adjusting Estimates

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 297

10/22/2010

Daily Note

Pages: 4

Upcoming Events for the Week of October 24

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 298

10/18/2010

Company Report

Pages: 7

Initiates Cystic Fibrosis Phase IIa Combination Study

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 299

10/07/2010

Company Report

Pages: 19

Initiating Coverage with a Buy Rating and Price Target of $45

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: BERNARDINO V

Price: 50.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 300

10/04/2010

Daily Note

Pages: 130

2010 AASLD Preview from Full Abstracts.

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 150.00

Research Provided by a Third Party